Journal article
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series
E Domingo, C Camps, PJ Kaisaki, MJ Parsons, D Mouradov, MM Pentony, S Makino, M Palmieri, RL Ward, NJ Hawkins, P Gibbs, H Askautrud, D Oukrif, H Wang, J Wood, E Tomlinson, Y Bark, K Kaur, EC Johnstone, C Palles Show all
Lancet Gastroenterology and Hepatology | ELSEVIER INC | Published : 2018
Abstract
Background: Molecular indicators of colorectal cancer prognosis have been assessed in several studies, but most analyses have been restricted to a handful of markers. We aimed to identify prognostic biomarkers for colorectal cancer by sequencing panels of multiple driver genes. Methods: In stage II or III colorectal cancers from the QUASAR 2 open-label randomised phase 3 clinical trial and an Australian community-based series, we used targeted next-generation sequencing of 82 and 113 genes, respectively, including the main colorectal cancer drivers. We investigated molecular pathways of tumorigenesis, and analysed individual driver gene mutations, combinations of mutations, or global measure..
View full abstractGrants
Awarded by Cancer Therapeutics Cooperative Research Centre
Funding Acknowledgements
UK Technology Strategy Board, National Institute for Health Research Oxford Biomedical Research Centre, Cancer Australia Project, Cancer Council Victoria, Ludwig Institute for Cancer Research, Victorian Government.